vs

Side-by-side financial comparison of Armour Residential REIT, Inc. (ARR) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

Armour Residential REIT, Inc. is the larger business by last-quarter revenue ($50.4M vs $35.5M, roughly 1.4× RECURSION PHARMACEUTICALS, INC.). Armour Residential REIT, Inc. runs the higher net margin — 420.2% vs -304.2%, a 724.5% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 297.9%). Over the past eight quarters, Armour Residential REIT, Inc.'s revenue compounded faster (108.0% CAGR vs 60.5%).

Armour Residential REIT, Inc. is a U.S.-based real estate investment trust that primarily invests in agency residential mortgage-backed securities guaranteed by U.S. government-sponsored entities. It focuses on generating consistent long-term net income for shareholders via strategic asset management and active interest rate risk mitigation.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

ARR vs RXRX — Head-to-Head

Bigger by revenue
ARR
ARR
1.4× larger
ARR
$50.4M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+383.9% gap
RXRX
681.7%
297.9%
ARR
Higher net margin
ARR
ARR
724.5% more per $
ARR
420.2%
-304.2%
RXRX
Faster 2-yr revenue CAGR
ARR
ARR
Annualised
ARR
108.0%
60.5%
RXRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARR
ARR
RXRX
RXRX
Revenue
$50.4M
$35.5M
Net Profit
$211.7M
$-108.1M
Gross Margin
59.8%
Operating Margin
-304.8%
Net Margin
420.2%
-304.2%
Revenue YoY
297.9%
681.7%
Net Profit YoY
555.9%
39.6%
EPS (diluted)
$2.43
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARR
ARR
RXRX
RXRX
Q4 25
$50.4M
$35.5M
Q3 25
$38.5M
$5.2M
Q2 25
$33.1M
$19.2M
Q1 25
$36.3M
$14.7M
Q4 24
$12.7M
$4.5M
Q3 24
$26.1M
Q2 24
$7.0M
$14.4M
Q1 24
$13.8M
Net Profit
ARR
ARR
RXRX
RXRX
Q4 25
$211.7M
$-108.1M
Q3 25
$159.3M
$-162.3M
Q2 25
$-75.6M
$-171.9M
Q1 25
$27.3M
$-202.5M
Q4 24
$-46.4M
$-178.9M
Q3 24
$-95.8M
Q2 24
$-48.4M
$-97.5M
Q1 24
$-91.4M
Gross Margin
ARR
ARR
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
ARR
ARR
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-3327.6%
Q2 25
-916.8%
Q1 25
-1297.9%
Q4 24
-4042.4%
Q3 24
-377.1%
Q2 24
-697.4%
Q1 24
-698.4%
Net Margin
ARR
ARR
RXRX
RXRX
Q4 25
420.2%
-304.2%
Q3 25
413.5%
-3135.3%
Q2 25
-228.4%
-894.2%
Q1 25
75.2%
-1373.3%
Q4 24
-366.8%
-3935.5%
Q3 24
-367.5%
Q2 24
-693.8%
-676.6%
Q1 24
-662.4%
EPS (diluted)
ARR
ARR
RXRX
RXRX
Q4 25
$2.43
$-0.17
Q3 25
$1.49
$-0.36
Q2 25
$-0.94
$-0.41
Q1 25
$0.32
$-0.50
Q4 24
$-0.91
$-0.56
Q3 24
$-0.34
Q2 24
$-1.05
$-0.40
Q1 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARR
ARR
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$63.3M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$2.3B
$1.1B
Total Assets
$21.0B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARR
ARR
RXRX
RXRX
Q4 25
$63.3M
$743.3M
Q3 25
$44.2M
$659.8M
Q2 25
$141.2M
$525.1M
Q1 25
$49.1M
$500.5M
Q4 24
$68.0M
$594.4M
Q3 24
$427.6M
Q2 24
$126.6M
$474.3M
Q1 24
$296.3M
Total Debt
ARR
ARR
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
ARR
ARR
RXRX
RXRX
Q4 25
$2.3B
$1.1B
Q3 25
$2.1B
$1.0B
Q2 25
$1.7B
$919.1M
Q1 25
$1.7B
$933.9M
Q4 24
$1.4B
$1.0B
Q3 24
$524.6M
Q2 24
$1.2B
$584.4M
Q1 24
$401.2M
Total Assets
ARR
ARR
RXRX
RXRX
Q4 25
$21.0B
$1.5B
Q3 25
$19.4B
$1.4B
Q2 25
$16.2B
$1.3B
Q1 25
$15.5B
$1.3B
Q4 24
$13.5B
$1.4B
Q3 24
$726.5M
Q2 24
$10.1B
$775.9M
Q1 24
$557.8M
Debt / Equity
ARR
ARR
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARR
ARR
RXRX
RXRX
Operating Cash FlowLast quarter
$124.2M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
0.59×
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARR
ARR
RXRX
RXRX
Q4 25
$124.2M
$-46.1M
Q3 25
$-37.8M
$-117.4M
Q2 25
$25.0M
$-76.4M
Q1 25
$101.5M
$-132.0M
Q4 24
$261.5M
$-115.4M
Q3 24
$-59.2M
Q2 24
$27.1M
$-82.2M
Q1 24
$-102.3M
Free Cash Flow
ARR
ARR
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
ARR
ARR
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
ARR
ARR
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
ARR
ARR
RXRX
RXRX
Q4 25
0.59×
Q3 25
-0.24×
Q2 25
Q1 25
3.71×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons